Noncoding mutations drive persistence of a founder pre-leukemic clone which initiates late relapse in T-ALL
- Author(s)
- O'Connor, D; Espejo Valle-Inclán, J; Conde, L; Bloye, G; Rahman, S; Costa, JR; Bartram, J; Adams, SP; Wright, G; Elrick, H; Wall, K; Dyer, SA; Howell, C; Jigoulina, G; Herrero, J; Cortes-Ciriano, I; Moorman, AV; Mansour, MR;
- Details
- Publication Year 2024-01-09,Volume 143,Issue #10,Page 933-937
- Journal Title
- Blood
- Publication Type
- Research article
- Abstract
- T-ALL relapse usually occurs early but can occur much later, which has been suggested to represent a de novo leukemia. However, we conclusively demonstrate late relapse can evolve from a pre-leukemic subclone harbouring a non-coding mutation that evades initial chemotherapy.
- Publisher
- American Society of Hematology
- Department(s)
- Laboratory Research
- Publisher's Version
- https://doi.org/10.1182/blood.2023021906
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-03-13 05:27:11
Last Modified: 2024-03-13 05:27:28